Akt3 - thymoma viral proto-oncogene 3 Gene

Also Known as Nmf350; D930002M15Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 23797

About Akt3

Chromosome 1: 176,847,639-177,085,769 reverse strand.GRCm39:CM000994.3

This gene has 4 transcripts (splice variants), 203 orthologues, 5 paralogues and is associated with 19 phenotypes. Broad expression in CNS E18 (RPKM 12.2), CNS E14 (RPKM 1.5) and 22 other tissues.

Summary

Predicted to enable ATP binding activity; protein kinase C binding activity; and protein serine/threonine kinase activity. Involved in positive regulation of angiogenesis and positive regulation of artery morphogenesis. Acts upstream of or within several processes, including brain morphogenesis; positive regulation of TOR signaling; and positive regulation of cell size. Predicted to be located in plasma membrane. Is expressed in several structures, including genitourinary system; musculature; nervous system; retina; and skin. Human ortholog(s) of this gene implicated in colon cancer; glioblastoma; prostate adenocarcinoma; prostate cancer; and renal cell carcinoma. Orthologous to human Akt3 (Akt serine/threonine kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Akt3 Products (1)

mRNA Protein Name
NM_011785.4 NP_035915.3 RAC-gamma serine/threonine-protein kinase

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables protein binding IPI
IPI: Inferred from physical interaction
18160256 MGI
Biological Process GO Annotation Evidence References Source
acts upstream of or within brain morphogenesis IMP
IMP: Inferred from mutant phenotype
15713641 MGI
acts upstream of or within homeostasis of number of cells within a tissue IMP
IMP: Inferred from mutant phenotype
15713641 MGI
acts upstream of or within positive regulation of TOR signaling IMP
IMP: Inferred from mutant phenotype
15713641 MGI
involved in positive regulation of angiogenesis IMP
IMP: Inferred from mutant phenotype
28254819 MGI
involved in positive regulation of artery morphogenesis IMP
IMP: Inferred from mutant phenotype
28254819 MGI
acts upstream of or within positive regulation of cell size IMP
IMP: Inferred from mutant phenotype
15713641 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Akt3 Protein Structure

PH_PKB

PH_PKB: cd01241 (3 - 109)

STKc_PKB_gamma

STKc_PKB_gamma: cd05593 (131 - 478)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 479 a.a.
Protein Preferred Names Protein Names

RAC-gamma serine/threonine-protein kinase

  • PKB gamma

  • RAC-PK-gamma

  • protein kinase Akt-3

  • protein kinase B gamma

Recombinant Akt3 Proteins

Cat. No. Product Name Accession Purity
HY-P72817 AKT3 Protein, Mouse (Active, sf9) Q9WUA6-1 (A106-E479) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-15431 Capivasertib Inhibitor 99.96% Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99118 Serplulimab Inducer 99.30% Unkown

Clinical Phase

Bioactive Molecules (13)
Cat. No. Product Name Effect
Purity Phase
HY-15727 Afuresertib Inhibitor 99.53% Phase 3
HY-15186A Ipatasertib dihydrochloride Inhibitor 99.27% Phase 3
HY-15186C Ipatasertib tosylate Inhibitor / Phase 3
HY-19719 Miransertib Inhibitor 99.32% Phase 2
HY-108232 MK-2206 Inhibitor 99.72% Phase 2
HY-15965 Uprosertib Inhibitor 99.93% Phase 2
HY-19934 Pifusertib Inhibitor 99.81% Phase 2
HY-10358 MK-2206 dihydrochloride Inhibitor 99.99% Phase 1
HY-10249 GSK-690693 Inhibitor 99.03% Phase 1
HY-100018 BAY1125976 Inhibitor 99.52% Phase 1
HY-16071 AT13148 Inhibitor 99.20% Phase 1
HY-137458A Vevorisertib trihydrochloride Inhibitor 99.60% Phase 1
HY-100501 M2698 Inhibitor 99.74% Phase 1

Pre-clinical Phase

Bioactive Molecules (27)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-15186 Ipatasertib Inhibitor 99.88% Yes
HY-10355 AKT inhibitor VIII Inhibitor 98.97% Unkown
HY-10425 Rizavasertib Inhibitor 99.04% Unkown
HY-133120 INY-03-041 Inhibitor 99.74% Unkown
HY-151504 Engasertib Inhibitor 99.65% Unkown
HY-12059 AT7867 Inhibitor 99.85% Unkown
HY-19934A Pifusertib hydrochloride Inhibitor 99.90% Unkown
HY-19982 AKT-IN-6 Inhibitor 99.08% Unkown
HY-15727A Afuresertib hydrochloride Inhibitor 99.95% Yes
HY-19719A Miransertib hydrochloride Inhibitor 99.74% Yes
HY-145282 MS170 Inhibitor 98.68% Unkown
HY-12059A AT7867 dihydrochloride Inhibitor 99.73% Unkown
HY-137458 Vevorisertib Inhibitor 98.03% Unkown
HY-133120A INY-03-041 trihydrochloride Inhibitor 99.78% Unkown
HY-132302 Hu7691 Inhibitor 99.91% Unkown
HY-129119 Akt1/Akt2-IN-2 Inhibitor 98.57% Unkown
HY-151613 MS15 Inhibitor / Unkown
HY-126257 AKT-IN-3 Inhibitor 98.12% Unkown
HY-143883 MS143 Degrader 97.8% Unkown
HY-132302A Hu7691 free base Inhibitor / Unkown
HY-145281 MS98 Inhibitor / Unkown
HY-10357 MK-2206 free base Inhibitor / Unkown
HY-175976 Akt3 ligand-1 Inhibitor / Unkown
HY-175975 PROTAC Akt3 Degrader-1 Degrader / Unkown
HY-143611 AKT-IN-8 Inhibitor / Unkown
HY-16032 Akt1-IN-2 Inhibitor 99.83% Unkown
HY-15965A Uprosertib hydrochloride Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Akt3 NCBI NCBI:10000